Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis

The survival of patients with melanoma of unknown primary (MUP) is proposed to be more favourable than that for melanoma of known primary (MKP). This may be due to an enhanced initial immune response in patients with MUP, which could also affect the efficacy of immunotherapy in advanced disease. The present study compared therapeutic outcome and survival in Stage III and IV MUP and MKP. Medical records of 67 MUP and 536 MKP patients were reviewed. Median overall survival (OS) in Stage III patients was 77 months versus 54 months in patients with MUP and MKP, respectively (p = 0.11). Median OS was prolonged in MUP patients receiving adjuvant first-line ipilimumab (p = 0.14). In contrast, OS tended to be more favourable in patients with MKP after palliative first-line ipilimumab treatment (p = 0.16). Yet, no statistically significant differences in OS were detected between the groups. Moreover, survival after anti-PD-1-antibody treatment was similar in patients with MUP and MKP. Overall, we observed similar survival outcomes after immunotherapy in patients with MUP and MKP. These findings provide no evidence of difference in responsiveness to immunotherapy between patients with MUP and MKP.

[1]  C. Verhoef,et al.  Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study , 2019, International journal of cancer.

[2]  Jeffrey F Scott,et al.  Stage IV melanoma of unknown primary: A population‐based study in the United States from 1973 to 2014 , 2018, Journal of the American Academy of Dermatology.

[3]  J. Wolchok,et al.  5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. , 2018 .

[4]  C. Lebbé,et al.  Epidemiological study of unknown primary melanoma patients from the French national melanoma database RIC-Mel. , 2018 .

[5]  D. Schadendorf,et al.  Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. , 2017, European journal of cancer.

[6]  P. Kučerová,et al.  Spontaneous regression of malignant melanoma - is it based on the interplay between host immune system and melanoma antigens? , 2017, Anti-cancer drugs.

[7]  I. Osman,et al.  Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature , 2017, Oncology.

[8]  J. Taube,et al.  Melanoma subtypes demonstrate distinct PD-L1 expression profiles. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[9]  D. Schadendorf,et al.  Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Braun,et al.  Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland , 2017, Melanoma research.

[11]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[12]  P. Nagarajan,et al.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[13]  R. Sullivan,et al.  Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies , 2016, Cancer.

[14]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[15]  J. Wolchok,et al.  Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. , 2016, The oncologist.

[16]  Jedd D. Wolchok,et al.  Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2016 .

[17]  A. Hauschild,et al.  Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? , 2015, Melanoma research.

[18]  C. Berking,et al.  Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor. , 2015, Discovery medicine.

[19]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[20]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[21]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[22]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[23]  G. McArthur,et al.  Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma , 2014, The Medical journal of Australia.

[24]  K. Shannon,et al.  Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease , 2014, Annals of Surgical Oncology.

[25]  K. Dutton-Regester,et al.  Melanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma , 2013, Pigment cell & melanoma research.

[26]  A. Gakiya,et al.  Malignant Melanoma of Unknown Primary Origin , 2013 .

[27]  L. Kiemeney,et al.  Melanoma of unknown primary origin: a population-based study in the Netherlands. , 2013, European journal of cancer.

[28]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[29]  N. Pavlidis,et al.  Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. , 2011, Critical reviews in oncology/hematology.

[30]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Garbe,et al.  Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma , 1997, Cancer.

[32]  A. Cochran,et al.  Nodal nevi and cutaneous melanomas. , 1996, The American journal of surgical pathology.

[33]  K. Mclaren,et al.  Histological regression in primary cutaneous melanoma: recognition, prevalence and significance , 1992, Histopathology.

[34]  S. Benjamin,et al.  Malignant melanoma primary in lymph node. The case of the missing link. , 1987, The American journal of surgical pathology.

[35]  H. Thaler,et al.  Nevus cell aggregates associated with lymph nodes: Estimated frequency and clinical significance , 1977, Cancer.

[36]  J. Stehlin,et al.  Spontaneous regression of primary malignant melanomas with regional metastases , 1965, Cancer.

[37]  J. Berg,et al.  MALIGNANT MELANOMA OF UNKNOWN PRIMARY ORIGIN. , 1963, Surgery, gynecology & obstetrics.

[38]  S. Li,et al.  BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. , 2017, Neoplasma.

[39]  Yoon Young Choi,et al.  Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. , 2015, Journal of the American Academy of Dermatology.

[40]  A. Hauschild,et al.  Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[42]  S. McCarthy,et al.  NAEVUS CELLS IN LYMPH NODES , 1974, Pathology.